Alzheimer’s Association Welcomes U.S. FDA Traditional Approval of Leqembi

July 6, 2023 — “The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to grant traditional approval of Leqembi^® (lecanemab, Eisai/Biogen) for the treatment of early Alzheimer’s disease with confirmation of elevated amyloid beta. This is the first traditional approval of an Alzheimer’s treatment that changes the underlying course of the disease.”

This article, Alzheimer’s Association Welcomes U.S. FDA Traditional Approval of Leqembi from the Alzheimer’s Association, explains the newly approved treatment for early Alzheimer’s disease.

“This treatment, while not a cure, gives people in the early stages of Alzheimer’s disease more time to maintain their independence and do the things they love,” said Joanne Pike, DrPH, Alzheimer’s Association president and CEO. “While we continue efforts to discover new targets and test new treatments, people living with this fatal disease deserve the opportunity to discuss and make the choice with their doctor if an FDA-approved treatment is right for them.”

Read the full article here